Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03568071
Other study ID # MOR106-CL-201
Secondary ID 2017-001142-10
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 26, 2018
Est. completion date March 3, 2020

Study information

Verified date March 2020
Source Galapagos NV
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II, randomized, double-blind, placebo-controlled multicenter study of repeated doses of MOR106 administered as IV infusion. MOR106, is an antibody which is being developed as a treatment for diseases such as psoriasis and atopic dermatitis. An antibody is a protein that is made by the body in a defense reaction against viruses and bacteria or other small particles. In this case, MOR106 will act against IL-17C interleukin by binding to it. This way it could be possible to act against these diseases.


Recruitment information / eligibility

Status Terminated
Enrollment 207
Est. completion date March 3, 2020
Est. primary completion date March 3, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female between 18-65 years of age (extremes included), on the day of signing informed consent form (ICF).

- Able and willing to give voluntary written informed consent and meet all of the inclusion criteria and none of the exclusion criteria before being enrolled in the study. The subjects must sign the informed consent form prior to any study-related procedures and agree to the schedule of assessments.

- A body mass index (BMI) between =18 and =30 kg/m².

- Diagnosis of chronic atopic dermatitis with at least 1 year since first diagnosis, as per the Hanifin and Rajka Criteria, fulfilling the following criteria:

1. EASI =12 at screening and =16 at baseline (Day 1 pre-dose).

2. Investigator's Global Assessment (IGA) score =3 (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe) at screening and at baseline.

3. Greater than or equal to 10% body surface area (BSA) of atopic dermatitis involvement at screening.

4. Willingness to continue stable use of an additive free, basic, bland emollient twice daily for at least 7 days before baseline and throughout the study.

5. Subject is a candidate for systemic therapy and has a history of inadequate response or has a contraindication to topical corticosteroids and/or topical calcineurin inhibitors before screening visit, as per investigator's opinion.

- Willing to adhere to the following contraceptive restrictions:

1. Female subjects of childbearing potential must have a negative serum pregnancy test at screening, and a negative urine pregnancy test at baseline.

2. Female subjects of childbearing potential must use a highly effective method of contraception from 28 days prior to the first dose of study drug, during the study, and for at least 24 weeks after the last dose of study drug.

3. Non-vasectomized male subjects with a female partner of childbearing potential must agree to a highly effective form of contraception during the study, and for at least 24 weeks after last dose of study drug.

4. All male subjects must agree to use a condom from the first dose of Investigational Medicinal Product (IMP), during the study and for at least 24 weeks after the last dose of IMP.

Exclusion Criteria:

- Known hypersensitivity to study drug ingredients or history of any significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.

- Prior treatment with MOR106.

- Positive serology for hepatitis B (positive hepatitis B surface [HBs] antigen and/or positive hepatitis core antibody [HBc]), or hepatitis C virus (HCV) antibody or any history of hepatitis from any cause with the exception of hepatitis A. Subjects who are immune to hepatitis B because of vaccination can be included.

- History of or current immunosuppressive condition (e.g., human immunodeficiency virus [HIV] infection), including history of invasive opportunistic infections (e.g., TB, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), despite infection resolution or unusually frequent, recurrent, or prolonged infections, per investigator judgment.

- Subjects with a history of Varicella zoster virus who experienced any episode or recurrence of Herpes Zoster infection within 1 year of screening or = one episode or Herpes Zoster within 1 year of screening must be excluded. (A history of Herpes simplex types 1 and 2 and vaginal candidiasis are permitted.)

- Pregnant or breast feeding female or subject is intending to become pregnant or breastfeed.

- Any concurrent illness, condition, disability, or clinically significant abnormality (including laboratory tests, = New York Heart Association Classification (NYHA) III/IV) or clinically significant illness in the 3 months prior to initial study drug administration that, in the investigator's opinion, represents a safety risk for the subject's participation in the study, may affect the interpretation of clinical safety or efficacy data, or may prevent the subject from safely completing the assessments required by the protocol.

- Any of the following laboratory findings:

1. White blood cell count <3.0 x 109 cells/L

2. Neutrophil count <1.5 x 109 cells/L

3. Platelet count <100 x 109 cells/L

4. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 x upper limit of normal (ULN)

- History of malignancy within the past 5 years prior to screening with the exception of non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or of the breast, prostate cancer T1a or T1b using the TNM (tumour, nodes, metastasis) clinical staging system.

- Clinically significant abnormalities at the discretion of the investigator detected on vital signs or physical examination (other than atopic dermatitis) at screening or baseline (Day 1 pre-dose).

- History of eczema herpeticum in the last 12 months prior to screening.

- Subjects who have had an attenuated vaccination within 4 weeks of baseline or are expected to have one during the course of the study.

- Participation in another experimental therapy study within 5 times the half-life (if known) or 12 weeks (if not known) of the experimental therapy, prior to baseline, or current enrollment in any other interventional study.

- Having used any of the following treatments:

1. Exposure to a biologic therapy for atopic dermatitis

2. Immunosuppressive/ immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon-gamma, azathioprine, methotrexate) within 4 weeks of baseline

3. Phototherapy (ultraviolet [UV] B or psoralen and ultraviolet A [PUVA]) for atopic dermatitis within 4 weeks of baseline

4. Treatment with topical corticosteroids or topical calcineurin inhibitors within 2 weeks of baseline

5. Treatment with biologics (for non atopic dermatitis indications within 5 half-lives (if known) or 12 weeks prior to baseline (if unknown)

6. Regular use (more than 2 visits per week) of a tanning booth/parlour within 4 weeks of screening

- Active chronic or acute infection requiring treatment with systemic (oral, SC or IV) antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals, within 4 weeks of baseline, or clinical signs of infective eczema within 1 week before baseline. Note: subjects may be rescreened after infection resolves.

- Investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof, who is directly involved in the conduct of the study.

- Not able to manage the electronic diary (e-diary) as per assessment of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MOR 106
The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
Placebo
A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.

Locations

Country Name City State
Germany Fachklinik Bad Bentheim, Department of Dermatology Bad Bentheim
Germany Charite, Universitätsmedizin Berlin, Centrum 12, Klinik für Dermatologie, Venerologie und Allergologie Berlin
Germany Korsearch. Studienzentrum Berlin
Germany Hautarztpraxis im Jahrhunderthaus Bochum
Germany Hauttumorzentrum Ruhr- Universität Bochum Bochum
Germany RuhrDerm - Studienzentrum der Gemeinschaftspraxis für Dermatologie, Venerologie, Allergologie, Phlebologie Bochum
Germany Elbe Klinikum Buxtehude Buxtehude
Germany Universitätsklinikum Frankfurt, Klinik für Dermatologie Frankfurt
Germany SCIderm GmbH (a company of TFS group) Hamburg
Germany Universitätsklinikum Heidelberg, Hautklinik Heidelberg
Germany Institut für Entzündungsmedizin Lubeck
Germany Clinical research center (CRC), Department of Dermatology Mainz
Germany Klinik und Poliklinik der Dermatologie und Allergologie der Universität München München
Germany Technical University Munich, Department of Dermatology Munich
Germany University Hospital of Muenster, Dpt. of Dermatology Münster
Germany Haut- und Lasercentrum Potsdam Potsdam
Hungary Budai Irgalmasrendi Kórház (St. John Hospital) Budapest
Hungary Semmelweis Egyetem Borgyógyászati Klinika Budapest
Hungary Bács-Kiskun Megyei Kórház Borgyógyászati Osztály Kecskemét
Hungary Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház Miskolc
Hungary Szegedi Egyetem Borgyógyászati és Allergológiai Klinika Szeged
Poland CERMED Bialystok
Poland Antoni Jurasz Universiti Hospital Nº1 Bydgoszcz
Poland NZOZ Centrum Medyczne KERmed Bydgoszcz
Poland A-DERM-SERWIS NZOZ , Przychodnia Specjalistyczna Czestochowa
Poland Centrum Badan Klinicznych PI-House Gdansk
Poland Gyncentrum Katowice
Poland Centrum Medyczne ALL-MED Kraków
Poland Diamond Clinic Kraków
Poland Medical Center Dietla 19 Kraków
Poland NZOZ Centrum Medyczne proMimed Kraków
Poland ETG Lódz Lódz
Poland KLIMED Marek Klimkiewicz Lomza
Poland Prywatny Gabinet Lekarski Urszula Chyrchel-Paszkiewicz Lublin
Poland Samodzielny Publiczny Szpital Kliniczny nr 1 Katedra i Klinika Dermatologii, Wenerologii i Dermatologii Dzieciecej Lublin
Poland Labderm sc Beata Bergler-Czop Barbara Sido-Bergler Ossy
Poland Dermedic Jacek Zdybski Ostrowiec Swietokrzyski
Poland Ostrowieckie Centrum Medyczne Ostrowiec Swietokrzyski
Poland KLIMED Marek Klimkiewicz Piotrków Trybunalski
Poland Centrum Badan Klinicznych S.C. Poznan
Poland Centrum Medyczne Grunwald Poznan
Poland Clinical Research Center Sp. z o.o. Medic-R Spólka Komandytowa Poznan
Poland ETG Skierniewice Skierniewice
Poland Centrum Medyczne AMED Warsaw
Poland ETG Warszawa Warsaw
Poland Clinical Research Group Warszawa
Poland 4HEALTH Wroclaw
Poland Dobrostan Wroclaw
Slovakia University Hospital Bratislava Bratislava
United Kingdom Whipps Cross Hospital Leytonstone
United Kingdom Plymouth Hospitals NHS Trust Plymouth
United Kingdom Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital Sheffield
United Kingdom The Royal London Hospital Whitechapel

Sponsors (1)

Lead Sponsor Collaborator
Galapagos NV

Countries where clinical trial is conducted

Germany,  Hungary,  Poland,  Slovakia,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106 as assessed by percentage change from baseline in EASI score at Day 85 visit. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. From baseline to Day 85
Secondary Proportion of subjects who achieve =50% overall improvement in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. From baseline to Day 85
Secondary Proportion of subjects who achieve =50% overall improvement in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. At Day 1
Secondary Proportion of subjects who achieve =50% overall improvement in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. At Day 15
Secondary Proportion of subjects who achieve =50% overall improvement in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. At Day 29
Secondary Proportion of subjects who achieve =50% overall improvement in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. At Day 43
Secondary Proportion of subjects who achieve =50% overall improvement in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. At Day 57
Secondary Proportion of subjects who achieve =50% overall improvement in Eczema Area and Severity Index (EASI) score. To assess the clinical efficacy of repeated IV doses of MOR106. The EASI score ranges are between 0 (no eczema) and 72. Higher values represent a worse outcome. At Day 71
Secondary Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 85
Secondary Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 1
Secondary Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 15
Secondary Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 29
Secondary Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 43
Secondary Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 57
Secondary Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 71
Secondary Proportion of subjects who achieve Investigators' Global Assessment (IGA) score reduction of =2. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 85
Secondary Proportion of subjects who achieve Investigators' Global Assessment (IGA) score reduction of =2. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 1
Secondary Proportion of subjects who achieve Investigators' Global Assessment (IGA) score reduction of =2. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 15
Secondary Proportion of subjects who achieve Investigators' Global Assessment (IGA) score reduction of =2. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 29
Secondary Proportion of subjects who achieve Investigators' Global Assessment (IGA) score reduction of =2. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 43
Secondary Proportion of subjects who achieve Investigators' Global Assessment (IGA) score reduction of =2. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 57
Secondary Proportion of subjects who achieve Investigators' Global Assessment (IGA) score reduction of =2. To assess the clinical efficacy of repeated IV doses of MOR106.The IGA is an assessment scale to determine severity of atopic dermatitis and clinical response to treatment based on a 5-point scale ranging from 0 (clear) to 4 (severe). At Day 71
Secondary Percent change in Scoring Atopic Dermatitis (SCORAD) score. To assess the clinical efficacy of repeated IV doses of MOR106. The SCORAD evaluates the extent of atopic dermatitis and ranges between 0 and 103. Higher values represent a worse outcome. From baseline to Day 85
Secondary Percent change in Scoring Atopic Dermatitis (SCORAD) score. To assess the clinical efficacy of repeated IV doses of MOR106. The SCORAD evaluates the extent of atopic dermatitis and ranges between 0 and 103. Higher values represent a worse outcome. At Day 1
Secondary Percent change in Scoring Atopic Dermatitis (SCORAD) score. To assess the clinical efficacy of repeated IV doses of MOR106. The SCORAD evaluates the extent of atopic dermatitis and ranges between 0 and 103. Higher values represent a worse outcome. At Day 15
Secondary Percent change in Scoring Atopic Dermatitis (SCORAD) score. To assess the clinical efficacy of repeated IV doses of MOR106. The SCORAD evaluates the extent of atopic dermatitis and ranges between 0 and 103. Higher values represent a worse outcome. At Day 29
Secondary Percent change in Scoring Atopic Dermatitis (SCORAD) score. To assess the clinical efficacy of repeated IV doses of MOR106. The SCORAD evaluates the extent of atopic dermatitis and ranges between 0 and 103. Higher values represent a worse outcome. At Day 43
Secondary Percent change in Scoring Atopic Dermatitis (SCORAD) score. To assess the clinical efficacy of repeated IV doses of MOR106. The SCORAD evaluates the extent of atopic dermatitis and ranges between 0 and 103. Higher values represent a worse outcome. At Day 57
Secondary Percent change in Scoring Atopic Dermatitis (SCORAD) score. To assess the clinical efficacy of repeated IV doses of MOR106. The SCORAD evaluates the extent of atopic dermatitis and ranges between 0 and 103. Higher values represent a worse outcome. At Day 71
Secondary The number of incidents of Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious Adverse Events (SAEs), and discontinuations due to Adverse Events (AEs). To assess the safety and tolerability of repeated IV doses of MOR106. From screening up to Day 197/early discontinuation (ED) visit
Secondary Characterization of the MOR106 immunogenetic profile. To assess the immunogenicity of repeated IV doses of MOR106. From baseline through Day 197/ED visit
Secondary MOR106 (AUC0-inf) To characterize the PK of repeated IV doses of MOR106. From baseline through Day 197/ED visit
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2